Amgen

Amgen (AMGN) is a publicly traded company in the Health Care sector, specifically within the Biotechnology industry. Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

The company reports trailing twelve-month revenue of $6.53B and net income of $1.82B.

Key metrics include a return on equity of 19.8%.

Investors tracking AMGN can follow price movements, analyst estimates, and fundamental changes directly through FINOTAUR's research tools.